Switch theme
Sign up to access all valuation multiples
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. It is developing a broad pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases. Palvella’s lead product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations (microcystic LMs) and cutaneous venous malformations.
2015
14
LTM Revenue n/a
LTM EBITDA -$19.1M
$186M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Palvella Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of -$19.1M.
In the most recent fiscal year, Palvella Therapeutics achieved revenue of n/a and an EBITDA of -$13.1M.
Palvella Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Palvella Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$11.9M | -$13.1M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$27.6M | $18.7M | XXX | XXX | XXX |
| Net Margin | -Infinity% | Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Palvella Therapeutics's stock price is $24.
Palvella Therapeutics has current market cap of $269M, and EV of $186M.
See Palvella Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $186M | $269M | XXX | XXX | XXX | XXX | $-6.19 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Palvella Therapeutics has market cap of $269M and EV of $186M.
Palvella Therapeutics's trades at n/a LTM EV/Revenue multiple, and -9.7x LTM EBITDA.
Analysts estimate Palvella Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Palvella Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $186M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -14.2x | XXX | XXX | XXX |
| P/E | -15.4x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -17.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpPalvella Therapeutics's NTM/LTM revenue growth is n/a
Palvella Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.0M for the same period.
Over next 12 months, Palvella Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Palvella Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Palvella Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 11% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.0M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Palvella Therapeutics acquired XXX companies to date.
Last acquisition by Palvella Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Palvella Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Palvella Therapeutics founded? | Palvella Therapeutics was founded in 2015. |
| Where is Palvella Therapeutics headquartered? | Palvella Therapeutics is headquartered in United States of America. |
| How many employees does Palvella Therapeutics have? | As of today, Palvella Therapeutics has 14 employees. |
| Who is the CEO of Palvella Therapeutics? | Palvella Therapeutics's CEO is Mr. Wesley H. Kaupinen. |
| Is Palvella Therapeutics publicy listed? | Yes, Palvella Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Palvella Therapeutics? | Palvella Therapeutics trades under PVLA ticker. |
| When did Palvella Therapeutics go public? | Palvella Therapeutics went public in 2024. |
| Who are competitors of Palvella Therapeutics? | Similar companies to Palvella Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Palvella Therapeutics? | Palvella Therapeutics's current market cap is $269M |
| What is the current EBITDA of Palvella Therapeutics? | Palvella Therapeutics's last 12-month EBITDA is -$19.1M. |
| What is the current EV/EBITDA multiple of Palvella Therapeutics? | Current EBITDA multiple of Palvella Therapeutics is -9.7x. |
| Is Palvella Therapeutics profitable? | Yes, Palvella Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
